Mesenchymal stem cells ameliorate diabetic glomerular fibrosis in vivo and in vitro by inhibiting TGF-β signalling via secretion of bone morphogenetic protein 7
Diabetic nephropathy (DN) is the leading cause of end-stage renal disease worldwide,1 with a significant increase in morbidity and mortality in patients with diabetes.2 Considering that currently available treatments involving…